Papaverine, 20 mg/ml 2 ml 10 pcs

Pharmacotherapeutic group:

Spasmodic agent (A03AD01).

Pharmacological group:

Papaverine reduces smooth muscle tone and has a vasodilator and antispasmodic effect in this regard.

It is an inhibitor of phosphodiesterase enzyme and causes intracellular accumulation of cyclic 3,5-adenosine monophosphate, which leads to disruption of smooth muscle contractility and their relaxation in spastic conditions.

The action of papaverine on the CNS is weak, only in high doses it has some sedative effect.

In large doses it reduces excitability of the heart muscle and slows intracardiac conduction.

Indications

Spasms of smooth muscles of abdominal organs, peripheral vessels and vessels of the brain, urinary tract, renal colic. It is used as an auxiliary agent for premedication.

Active ingredient

Composition

1 ml of the solution contains 0.02 g of papaverine hydrochloride.

Auxiliary substances:

dinatrium salt of ethylenediaminetetetraacetic acid (trilon B),

methionine,

water for injection.

How to take, the dosage

The drug is administered intramuscularly, subcutaneously or intravenously.

The single dose for adults is 0.02-0.04 g (1-2 ml of 2% solution); the interval between injections is at least 4 hours.

Intravenous administration is carried out having previously diluted 2% solution of the drug with 10-20 ml of sodium chloride isotonic solution.

In elderly patients the initial single dose should not exceed 0.01 g.

In children aged 1-12 years the maximum single dose is 0.3 mg/kg of body weight.

Interaction

Papaverine reduces the antiparkinsonian effect of levodopa.

In combination with barbiturates the antispasmodic effect of papaverine hydrochloride is increased.

When used in combination with tricyclic antidepressants, povcapamide, reserpine, quinidine sulfate, the hypotensive effect may be increased.

Special Instructions

The drug should be administered with caution and in small doses in elderly and frail patients as well as patients with craniocerebral trauma, hepatic and renal dysfunction, hypothyroidism, insufficient adrenal function, prostatic hypertrophy and patients with supraventricular tachycardia and those in a state of shock.

The drug should be administered intravenously slowly and under medical supervision. Intake of alcohol should be excluded during treatment. The safety of the drug has not been established in pregnancy and lactation.

Contraindications

Comatose state; respiratory depression; impaired atrioventricular conduction; age less than 1 year; hypersensitivity to the drug.

Side effects

Sleepiness, headache, nausea, constipation, increased sweating are possible.

In case of rapid intravenous administration, as well as when using high doses, atrioventricular block and cardiac arrhythmia may develop.